TY - JOUR
T1 - A proposal to prevent the "Mephisto Sign" side effect of botulinum toxin type a injection in chronic migraine
AU - Cho, Eunae S.
AU - Hwang, Jae Young
AU - Kim, Seong Taek
PY - 2013
Y1 - 2013
N2 - Botulinum toxin type A (BoNT-A) has been reported as an effective treatment for chronic migraine. When BoNT-A is injected on the frontalis muscle for chronic migraine, an unexpected clinical side effect called the "Mephisto sign" may occur. The aim of this article is to propose a method to eliminate or prevent the Mephisto sign side effect. A 25-year-old female patient visited the hospital and was diagnosed with chronic migraine. A total of 155 U of BoNT-A was injected into 31 sites. 2-weeks later, and the patient developed the Mephisto sign. An additional 2-U dose was administered bilaterally to the lateral-most point of the frontalis muscles, and the eyebrow morphology returned to normal within 2-3 weeks. We propose that the development of the Mephisto sign may be prevented with an additional BoNT-A injection of 2-4 U bilaterally to the lateral most point of the frontalis muscles during the primary injection process.
AB - Botulinum toxin type A (BoNT-A) has been reported as an effective treatment for chronic migraine. When BoNT-A is injected on the frontalis muscle for chronic migraine, an unexpected clinical side effect called the "Mephisto sign" may occur. The aim of this article is to propose a method to eliminate or prevent the Mephisto sign side effect. A 25-year-old female patient visited the hospital and was diagnosed with chronic migraine. A total of 155 U of BoNT-A was injected into 31 sites. 2-weeks later, and the patient developed the Mephisto sign. An additional 2-U dose was administered bilaterally to the lateral-most point of the frontalis muscles, and the eyebrow morphology returned to normal within 2-3 weeks. We propose that the development of the Mephisto sign may be prevented with an additional BoNT-A injection of 2-4 U bilaterally to the lateral most point of the frontalis muscles during the primary injection process.
UR - http://www.scopus.com/inward/record.url?scp=84886510242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886510242&partnerID=8YFLogxK
U2 - 10.3349/ymj.2013.54.6.1542
DO - 10.3349/ymj.2013.54.6.1542
M3 - Article
C2 - 24142664
AN - SCOPUS:84886510242
SN - 0513-5796
VL - 54
SP - 1542
EP - 1544
JO - Yonsei medical journal
JF - Yonsei medical journal
IS - 6
ER -